• Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
Search
Arvinas Logo
Arvinas logo
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
Search
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
  • Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
27MarMarch 27, 2024

The Effect of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, on Dabigatran Pharmacokinetics in Healthy Adult Participants

27MarMarch 27, 2024

Evaluation of the Effect of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, on Rosuvastatin Pharmacokinetics in Healthy Adult Participants

05DecDecember 5, 2023

Vepdegestrant, a PROteolysis Targeting Chimera (PROTAC) Estrogen Receptor Degrader, Plus Palbociclib in Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase 1b Cohort

05DecDecember 5, 2023

Updated Results From VERITAC Evaluating Vepdegestrant, a PROteolysis Targeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in ER–Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer

05DecDecember 5, 2023

TACTIVE-U: Phase 1b/2 Umbrella Study of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Combined With Other Anticancer Treatments in ER-Positive Advanced or Metastatic Breast Cancer

05DecDecember 5, 2023

VERITAC-2: A Phase 3 Study of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, vs Fulvestrant in ER Positive/Human Epidermal Growth Factor Receptor 2 (HER2) Negative Advanced Breast Cancer

05DecDecember 5, 2023

VERITAC-3: A Randomized Phase 3 Study, With a Lead in, of First Line Vepdegestrant + Palbociclib vs Letrozole + Palbociclib in Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer

05DecDecember 5, 2023

Leveraging a Pharmacokinetic /Pharmacodynamic (PK/PD) Model to Guide Dose Optimization of Palbociclib in Combination With Vepdegestrant

01DecDecember 1, 2023

Safety and Pharmacokinetics (PK) of Vepdegestrant in Japanese Patients With Estrogen Receptor (ER)+/Human Epidermal Growth Factor Receptor 2 (HER2) Advanced Breast Cancer: Results From a Japanese Phase 1 Study

01DecDecember 1, 2023

Global Phase 3 Studies Evaluating Vepdegestrant in Estrogen Receptor (ER)+/Human Epidermal Growth Factor Receptor 2 (HER2) Advanced Breast Cancer: VERITAC-2 and VERITAC-3

  Prev1234Next  
Arvinas logo
  • Careers
  • Privacy Policy
  • Terms of Use
LinkedIn
X

Accessibility Statement

© 2026 Arvinas. All rights reserved.

Arvinas

You are now leaving arvinas.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

GO BACK
CONTINUE